This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AMAG AMAG Pharmaceuticals (AMAG) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AMAG Pharmaceuticals Stock (NASDAQ:AMAG) 30 days 90 days 365 days Advanced Chart Get AMAG Pharmaceuticals alerts:Sign Up Key Stats Today's Range$13.75▼$13.7550-Day Range$13.69▼$13.7552-Week Range$4.41▼$13.80VolumeN/AAverage Volume950,664 shsMarket Capitalization$477.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. Read More Receive AMAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AMAG Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMAG Stock News HeadlinesAMAG Pharmaceuticals, Inc. (AMU.DE)June 26, 2025 | uk.finance.yahoo.comAera Therapeutics Appoints Paul Conrad, Ph.D., MBA, as Chief Business and Financial OfficerMay 13, 2025 | finance.yahoo.comBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most investors are still asleep… but not for long. Garrett Goggin’s latest research reveals how you can “front-run” the greatest investor alive by positioning in four small miners sitting on up to 100X potential upside. When this hits the news — it’ll be too late.July 2 at 2:00 AM | Golden Portfolio (Ad)Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial OfficerOctober 31, 2024 | markets.businessinsider.comTransoft Solutions Acquires Advanced Mobility Analytics Group (AMAG)October 15, 2024 | finance.yahoo.comKalVista Appoints Brian Piekos as Chief Financial OfficerSeptember 10, 2024 | finance.yahoo.comFull-Life Technologies Announces the Appointment of Edward (Ted) Myles to Its Board of DirectorsJuly 22, 2024 | msn.comGlobal Iron Drugs Strategic Business Report 2024: Market to Reach $11 Billion by 2030 with Oral Segment to Account for $6.7 BillionMay 14, 2024 | finance.yahoo.comSee More Headlines AMAG Stock Analysis - Frequently Asked Questions How were AMAG Pharmaceuticals' earnings last quarter? AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced its quarterly earnings data on Monday, May, 11th. The specialty pharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.27. The specialty pharmaceutical company had revenue of $68.66 million for the quarter, compared to analyst estimates of $64.95 million. AMAG Pharmaceuticals had a negative net margin of 74.93% and a negative trailing twelve-month return on equity of 16.92%. What other stocks do shareholders of AMAG Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that AMAG Pharmaceuticals investors own include Bristol Myers Squibb (BMY), Palatin Technologies (PTN), Gilead Sciences (GILD), Meta Platforms (META), Bausch Health Cos (BHC), Netflix (NFLX) and Tesla (TSLA). Company Calendar Last Earnings5/11/2020Today7/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:AMAG CIK792977 Webwww.amagpharma.com Phone617-498-3300FaxN/AEmployees440Year FoundedN/AProfitability EPS (Trailing Twelve Months)($6.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$466.46 million Net Margins-74.93% Pretax MarginN/A Return on Equity-16.92% Return on Assets-5.96% Debt Debt-to-Equity Ratio1.13 Current Ratio1.75 Quick Ratio1.45 Sales & Book Value Annual Sales$327.75 million Price / Sales1.46 Cash FlowN/A Price / Cash FlowN/A Book Value$7.37 per share Price / Book1.87Miscellaneous Outstanding Shares34,725,000Free FloatN/AMarket Cap$477.47 million OptionableOptionable Beta0.89 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:AMAG) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AMAG Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AMAG Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.